18 completed, 10 recruiting, 7 active not recruiting, 6 terminated. 48 Phase 3, 12 Phase 2.
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%) - Epidermolysis Bullosa (EB) | Phase 3 | Not yet recruiting | Paradigm Therapeutics | 80 | 2026-11-15 | 2026-09-09 |
| The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution - Ehlers-Danlos Syndrome, Low Back Pain | Phase 3 | Withdrawn | Tulane University | 2026-10-05 | 2026-10-08 | |
| Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa SD-101 Dermal Cream (6%), Vehicle (SD-101 0%) - Epidermolysis Bullosa (EB) | Phase 3 | Recruiting | Paradigm Therapeutics | 80 | 2026-07-21 | 2026-10-15 |
| Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome) Chang Ji'an capsule, Chang Ji'an capsule mimic - IBS, Diarrhea Predominant | Phase 3 | Not yet recruiting | Beijing Hospital of Traditional Chinese Medicine | 636 | 2026-05-31 | 2026-05-28 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Saccharomyces Boulardii 250 MG, Placebo 250 mg - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 3 | Recruiting | Biocodex | 406 | 2025-10-22 | 2025-11-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa KB803, Placebo - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Recruiting | Krystal Biotech, Inc. | 16 | 2025-06-20 | 2026-03-12 |
| A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa Oleogel-S10 - Epidermolysis Bullosa, Junctional Epidermolysis Bullosa | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 6 | 2025-04-18 | 2025-12-22 |
| Evaluation of D-Fi for the Treatment of Wounds Due to DEB D-Fi - Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Castle Creek Biosciences, LLC. | 32 | 2025-03-27 | 2026-03-13 |
| Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. Enzastaurin, Placebo - Vascular Ehlers-Danlos Syndrome | Phase 3 | Suspended | Aytu BioPharma, Inc. | 260 | 2025-01-01 | 2024-03-08 |
| An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) AC-203, Vehicle - Generalized Epidermolysis Bullosa Simplex | Phase 2 / Phase 3 | Active not recruiting | TWi Biotechnology, Inc. | 80 | 2024-04-04 | 2026-07-09 |
| Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) allo-APZ2-OTS, Placebo - Epidermolysis Bullosa | Phase 3 | Active not recruiting | RHEACELL GmbH & Co. KG | 9 | 2023-10-18 | 2025-12-10 |
| Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) allo-APZ2-OTS, Placebo - Epidermolysis Bullosa | Phase 3 | Active not recruiting | RHEACELL GmbH & Co. KG | 91 | 2023-06-13 | 2025-12-10 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum Etidronate, Placebo - Pseudoxanthoma Elasticum | Phase 3 | Recruiting | UMC Utrecht | 76 | 2023-04-26 | 2023-04-27 |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients EB-101 Surgical application of RDEB wounds - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase 3 | Active not recruiting | Abeona Therapeutics, Inc | 12 | 2023-04-02 | 2025-06-27 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita PTX-022 - Pachyonychia Congenita | Phase 3 | Recruiting | Palvella Therapeutics, Inc. | 45 | 2022-11-15 | 2022-12-09 |
| Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome ACER-002 (celiprolol) 200 mg BID, Placebo BID - Vascular Ehlers-Danlos Syndrome | Phase 3 | Recruiting | Acer Therapeutics Inc. | 150 | 2022-11-07 | 2025-08-24 |
Showing 20 of 48. Sign in to see all of them.
Epidermolysis Bullosa (14) · Epidermolysis Bullosa Dystrophica (10) · Netherton Syndrome (6) · Pachyonychia Congenita (4) · Ehlers-Danlos Syndrome, Type IV (3) · Ichthyosis Bullosa of Siemens (3) · Pruritus (3) · Epidermolysis Bullosa Simplex (2) · Epidermolysis Bullosa, Junctional (2) · Ichthyosis (2) · Ichthyosis, Lamellar (2) · Skin Diseases (2) · Anemia, Aplastic (1) · Blister (1) · Capillary Malformations, Congenital, 1 (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (48) · Skin and Connective Tissue Diseases (48) · Congenital Abnormalities (47) · Skin Diseases (46) · Skin Diseases, Genetic (45) · Genetic Diseases, Inborn (44) · Skin Diseases, Vesiculobullous (23) · Connective Tissue Diseases (14) · Infant, Newborn, Diseases (14) · Keratosis (14) · Collagen Diseases (13) · Ichthyosis (12) · Abnormalities, Multiple (10) · Epidermolysis Bullosa (9)
Alemtuzumab (1) · Antilymphocyte Serum (1) · BID protein, human (1) · Biological Dressings (1) · Bone Marrow Transplantation (1) · Brimonidine Tartrate (1) · Celiprolol (1) · Cyclophosphamide (1) · Drugs, Investigational (1) · Erythromycin (1) · Etidronic Acid (1) · Gels (1) · Glucose (1) · Injections (1) · Irbesartan (1)
Palvella Therapeutics, Inc. (4) · Quoin Pharmaceuticals (4) · Krystal Biotech, Inc. (3) · Abeona Therapeutics, Inc (2) · Assistance Publique - Hôpitaux de Paris (2) · Castle Creek Biosciences, LLC. (2) · Centre Hospitalier Universitaire de Nice (2) · Paradigm Therapeutics (2) · RHEACELL GmbH & Co. KG (2) · Scioderm, Inc. (2) · The Hospital for Sick Children (2) · University Hospital, Toulouse (2) · AGI Therapeutics, Inc. (1) · Acer Therapeutics Inc. (1) · Aldeyra Therapeutics, Inc. (1)
United States (30) · France (14) · United Kingdom (8) · Germany (7) · Italy (7) · Spain (7) · Austria (6) · Canada (6) · Australia (5) · Israel (5) · Netherlands (5) · Poland (5) · Portugal (4) · China (3) · Greece (3)
David Hansen, MD (2) · Elena Pope, MD (2) · Joyce Teng, MD (2) · Tony Andrasfay (2) · Alan Arbuckle, MD, FAAD, FAAP (1) · Amy Paller, MD (1) · Angela Iheanacho, MS (1) · Carl R. Thornfeldt (1) · Chiaverini Christine, Dr (1) · Christine Chiaverini, PH (1) · Damien Bates, MD, PhD, FRACS (Plast.) (1) · David Chien, MD (1) · Elizabeth Alvarez- Connelly, MD (1) · Jacques Courseault, MD (1)
PMID 20383216, PMID 20825986, PMID 23630948, PMID 24102348, PMID 31186047, PMID 32576219, PMID 32693833, PMID 36516090, PMID 39441591, PMID 39906986, PMID 40220208, PMID 40570869, PMID 41131563, PMID 42205007
2014 (2), 2015 (1), 2016 (1), 2017 (1)